Enovis Corp
NYSE:ENOV
Enovis Corp
Free Cash Flow
Enovis Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enovis Corp
NYSE:ENOV
|
Free Cash Flow
-$67.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Free Cash Flow
$2.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Free Cash Flow
$2.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Free Cash Flow
$3.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Free Cash Flow
$6.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Free Cash Flow
$586m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
Enovis Corp
Glance View
Enovis Corp., a company with a steadfast commitment to innovation and growth, operates within the specialized world of medical technology. Originally a part of Colfax Corporation, it underwent a strategic transformation, branching out into its own entity, laser-focused on advancing human mobility through cutting-edge orthopedic solutions. Enovis has carved its niche by developing and manufacturing high-quality, bespoke orthopedic products that serve both surgical and non-surgical needs. These offerings are designed to enhance patient recovery and mobility, thereby improving quality of life. Its extensive product portfolio includes surgical implants, bracing, rehabilitation solutions, and intelligent digital care platforms, positioning Enovis at the intersection of healthcare and technology. Revenue for Enovis streams from its diverse array of products and solutions targeted at healthcare professionals and institutions worldwide. The company thrives by engaging in both direct sales and a network of distributors to ensure its innovative solutions reach a broad spectrum of the healthcare landscape. By continually investing in research and development, Enovis maintains its competitive edge, launching new products that address evolving medical needs. This proactive approach not only caters to the existing demand but also stimulates new markets by educating and training medical professionals and leading them through transformative, evidence-based clinical outcomes. In essence, Enovis Corp. excels by integrating science and technology to fuel both financial growth and human betterment.
See Also
What is Enovis Corp's Free Cash Flow?
Free Cash Flow
-67.2m
USD
Based on the financial report for Dec 31, 2024, Enovis Corp's Free Cash Flow amounts to -67.2m USD.
You don't have any saved screeners yet